Bookmark and Share
BioAssay: AID 651694

Cytotoxicity Dose Response with AM2.2-beta2AR cells for PowderSet01

Assay Provider: Jonathan Jarvik, Carnegie Mellon University Screening Center/ PI: UNMCMD/ Larry Sklar ..more
_
   
 Tested Compounds
 Tested Compounds
All(8)
 
 
Active(2)
 
 
Inactive(6)
 
 
 Tested Substances
 Tested Substances
All(8)
 
 
Active(2)
 
 
Inactive(6)
 
 
 Related BioAssays
 Related BioAssays
AID: 651694
Data Source: NMMLSC (UNMCMD_b2AR_CYTOTOXICITY_PS01)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2012-10-23
Modify Date: 2012-12-05

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compounds: 2
Related Experiments
Show more
AIDNameTypeComment
504448Summary of HTS for Non-Canonical Ligands for Beta 2 Adrenergic Receptor InternalizationSummarydepositor-specified cross reference: Summary of HTS for Non-Canonical Ligands for Beta 2 Adrenergic Receptor Internalization
651701Summary of HTS Screening Project for Inhibitors of fluorogen-FAP tag interactionsSummarydepositor-specified cross reference: Summary of HTS Screening Project for Inhibitors of fluorogen-FAP tag interactions
485366qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptorConfirmatorysame project related to Summary assay
492947qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptorConfirmatorysame project related to Summary assay
504454HTS for Beta-2AR agonists via FAP methodScreeningsame project related to Summary assay
504459HTS for Beta-2AR agonists via FAP method from Validation SetScreeningsame project related to Summary assay
540358HTS for Beta-2AR agonists via FAP method, Single Point, Cherry Pick 1Othersame project related to Summary assay
588763Dose response for HTS for Beta-2AR agonists via FAP method from CP1Confirmatorysame project related to Summary assay
588765HTS for Beta-2AR agonists via FAP method, Counterscreen, Cherry Pick 1Othersame project related to Summary assay
588775Dose response for HTS for Beta-2AR agonists via FAP method from Powderset1Confirmatorysame project related to Summary assay
623882Dose response for HTS for Beta-2AR agonists via FAP method from Powderset2Confirmatorysame project related to Summary assay
623947Dose response for HTS for Beta-2AR agonists via FAP method from Powderset3Confirmatorysame project related to Summary assay
651698Counter screen for HTS for Beta-2AR agonists with FAP-tagged mouse CCR5 with Powderset1Confirmatorysame project related to Summary assay
588775Dose response for HTS for Beta-2AR agonists via FAP method from Powderset1Confirmatorysame project related to Summary assay
623882Dose response for HTS for Beta-2AR agonists via FAP method from Powderset2Confirmatorysame project related to Summary assay
623947Dose response for HTS for Beta-2AR agonists via FAP method from Powderset3Confirmatorysame project related to Summary assay
651698Counter screen for HTS for Beta-2AR agonists with FAP-tagged mouse CCR5 with Powderset1Confirmatorysame project related to Summary assay
651728Counter screen for HTS for Beta-2AR agonists with FAP-tagged human CCR5 with Powderset2Confirmatorysame project related to Summary assay
651729Counter screen for HTS for Beta-2AR agonists with FAP-tagged GPR32 with Powderset2Confirmatorysame project related to Summary assay
651853Counter screen for HTS for Beta-2AR agonists with FAP-tagged human GPR32 with Powderset3Confirmatorysame project related to Summary assay
651855Counter screen for HTS for Beta-2AR agonists with FAP-tagged human CCR5 with Powderset3Confirmatorysame project related to Summary assay
651870Cytotoxicity Dose Response with AM2.2-beta2AR cells for PowderSet4Confirmatorysame project related to Summary assay
651872Dose response for HTS for Beta-2AR agonists via FAP method from Powderset4Confirmatorysame project related to Summary assay
651873Counter screen for HTS for Beta-2AR agonists with FAP-tagged human CCR5 with Powderset4Confirmatorysame project related to Summary assay
651875Counter screen for HTS for Beta-2AR agonists with FAP-tagged GPR32 with Powderset4Confirmatorysame project related to Summary assay
651912Dose response for HTS for Beta-2AR agonists via FAP method from Powderset5Confirmatorysame project related to Summary assay
651913Counter screen for HTS for Beta-2AR agonists with FAP-tagged human CCR5 with Powderset5Confirmatorysame project related to Summary assay
651914Counter screen for HTS for Beta-2AR agonists with FAP-tagged GPR32 with Powderset5Confirmatorysame project related to Summary assay
651936Evaluation of reversibility of compound binding to AM2.2-beta2AR cells with Powder Set 3and4Othersame project related to Summary assay
651938Fluorogen/soluble FAP binding competition assayOthersame project related to Summary assay
Description:
University of New Mexico Assay Overview:
Assay Support: R03 MH093192-01
Project Title: HTS for Non-Canonical Ligands for Beta 2 Adrenergic Receptor Internalization
Assay Provider: Jonathan Jarvik, Carnegie Mellon University Screening Center/ PI: UNMCMD/ Larry Sklar
Lead Biologist: Yang Wu
Chemistry Center/ PI: Vanderbilt Specialty Chemistry Center/Craig Lindsley Chemistry Center Lead: Shaun Stauffer
Assay Implementation: Yang Wu, Phillip Tapia

Assay Background and Significance:

G protein-coupled receptors represent the largest family of proteins in the human genome with an estimated number of approximately 800. Because of their central involvement in almost every aspect of human physiology, they also represent the largest target for medical intervention [Lin and Civelli, Annu Med 36 (2004), 204-14]. Today, GPCRs represent the target of approximately 30-40% of all drugs on the market. Indeed, of the 50 top-selling drugs in the United States in 2007, 18 target GPCRs, with combined sales of approximately 25 billion dollars.

Of about 800 GPCRs, 500 are chemosensory, representing the chemokine/chemoattractant GPCRs, and the olfactory and gustatory GPCRs. Although the former have been thoroughly characterized for the most part, members of the latter, particularly the olfactory receptors which may include the important category of pheromones, have had only a small number of ligands identified. The remaining GPCRs, approximately 360, constitute the transmitter GPCRs. Of these, approximately 100 receptors still have no known ligand. Such receptors with no known physiological ligand are referred to as orphan receptors and arose from cloning strategies based on limited homology within almost all GPCRs (predominantly during the 1990's) as well as the sequencing of the human genome (in 2000) [Chung et al, Br J Pharmacol 153 Suppl 1 (2008), S339-46].

The search for endogenous ligands for orphan GPCRs has been challenging. This process has given rise to the field of reverse pharmacology, which uses orphan GPCRs to identify novel ligands, which together often lead to the characterization of new physiological paradigms. Over the last 20 years, this approach has led to the deorphanization of about 300 GPCRs. Many of the ligands were already known and their biology characterized, but their receptor was unknown. But in some of these instances, this process also led to the identification of novel transmitters [Civelli et al., Pharmacol Ther 110 (2006), 525-32].

During the 1990's, approximately 10 GPCRs were deorphanized per year. However, very few have been deorphanized since 2004. In addition, no novel transmitters have been identified since that time [Chung et al, Br J Pharmacol 153 Suppl 1 (2008), S339-46]. Given these facts, the question arises as to whether the remaining orphan GPCRs will be readily deorphanized. One major issue is that the pool of known transmitters for which no receptor is known has been essentially depleted. Since all the possible transmitters have now been matched to GPCRs, the current orphan GPCRs can only bind unknown ligands, for which the identification is also slow and resource intense. This is particularly true given that the concentrations of many transmitters in vivo is exceedingly low, making their identification difficult. It is also possible that the expression of some ligands may be developmentally or environmentally regulated.

Almost all current reverse pharmacological/screening approaches rely on monitoring second messenger levels such as calcium mobilization, cAMP production and transcriptional activation. Thus, successful screening requires knowledge of the pathway for a given receptor, in particular the G protein to which the receptor couples. As the number of heterotrimeric G protein combinations is large, this is not a trivial task.

An alternate approach to measuring signal transduction is the monitoring receptor internalization. Virtually all known GPCRs undergo activation-dependent internalization as a mechanism to reduce cell surface receptor numbers. Internalization does not require G protein coupling. Instead, the activity of one of four G protein receptor kinases (GRKs) is required. In most instances, the binding of an accessory protein, arrestin, is also required. One screening approach that has been developed is the recruitment of GFP-tagged arrestin to either the plasma membrane or intracellular endosomes.

The beta-Arrestin clustering assay, developed by Norak Technologies, requires high resolution imaging, well spread, adherent cells, and extensive image analysis to determine the response to a treatment. Other methods, such a receptor desensitization measurements on non-permeabilized cells rely on measurement of subtle changes in intensity. As described below, the CMU TCNP is developing sensors for GPCR responses that are readily compatible with HTS flow cytometry and multiplexing when the GPCRs are expressed in suspension cell lines.
Protocol
This assay will be used to determine if a compound is causing a decrease in signal by killing the cell instead of actually inhibiting beta2AR internalization.
CellTiter-Glo, a luminescent cell viability assay kit from Promega (Madison, WI), will be used according to the manufacturer's instruction. Briefly, the cell cultures of AM2.2-beta2AR cells are seeded in complete medium at twelve different cell densities in 96-well white polypropylene opaque plates (50 microL/well per 384 well) (Corning, Corning, NY). At the time of passage, 90microL of cell suspension (10^5 cells/milliL) are added into the plates. After stabilization for 2h, test compounds are added to the wells at 10 microL per well to a final concentration range of 380 nM to 100 microM. Vehicle control wells contain 0.01% DMSO alone. Following treatment, cells are incubated at 37 degrees C and 5% CO2 for 18 hours. At the end of the respective time point, 1x CellTiter-Glo is added to each well (10 microL/well per 384 well). Plates are read after 30 minutes. Luminescence intensity (LI) is collected using a Wallac 1420 plate reader (PerkinElmer, Norwalk, CT).
Calculations:
Background luminescence were subtracted from all readings and then luminescence values for the entire concentration range of a test compound were fitted by Prism(R) software (GraphPad Software, Inc., San Diego, CA) using nonlinear least-squares regression in a sigmoidal dose response model with variable slope, also known as the four parameter logistic equation. Curve fit statistics were used to determine the following parameters of the model: EC50, microM - concentration of added test compound competitor that inhibited fluorescent ligand binding by 50 percent; LOGEC50 - the logarithm of EC50; TOP - the response value at the top plateau; BOTTOM - the response value at the bottom plateau; HILLSLOPE - the slope factor, or the Hill coefficient; STD_LOGEC50, STD_TOP, STD_BOTTOM, STD_HILLSLOPE - standard errors of LOGEC50, TOP, BOTTOM, and HILLSLOPE ; EC50_95CI_LOW, EC50_95CI_HIGH - the low and high boundaries of the 95% confidence interval of the EC50 estimate, RSQR - the correlation coefficient (r squared) indicative of goodness-of-fit.
Compounds with percent viability at the highest concentration is less than 50% are labeled active and the PubChem_Score is calculated based on EC50 of cytotoxicity by the following equation:
PubChem Score = 100 * (1 - EC50/30 microM)
Keywords: beta2AR, UNMCMD
Categorized Comment - additional comments and annotations
From PubChem:
Assay Type: Toxicity
Assay Cell Type: AM2.2-beta2AR
From ChEMBL:
Assay Format: Cell-based
Assay Type: Functional
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1ACTIVITY_TYPEQualifier for the value of EC50String
2EC50_MICROM*Effective concentration of half maximal event count as estimated by curve fitFloatμM
3EC50_95CI_LOWLower 95% confidence interval boundary for the EC50 curve fit estimateFloatμM
4EC50_95CI_HIGHUpper 95% confidence interval boundary for the EC50 curve fit estimateFloatμM
5BOTTOMResponse value at the bottom plateauFloat%
6TOPResponse value at the top plateauFloat%
7LOGEC50Log of the EC50 estimateFloat
8HILLSLOPEHill slope estimate for the fitted dose response curveFloat
9STD_BOTTOMStandard error for the response value at the bottom plateauFloat%
10STD_TOPStandard error for the response value at the top plateauFloat%
11STD_LOGEC50Standard error for the Log EC50 valueFloat
12STD_HILLSLOPEStandard error for the HILL SLOPEFloat
13RSQR Correlation coefficient for the fitted dose response curveFloat
14N_POINTSNumber of data points for each dose response curveInteger
15Luminecence_0uM (0μM**)Average luminescence measured with DMSO, solvent for test compounds, n=2Float
16Luminecence_0.02uM (0.02μM**)Average luminescence measured with 0.02 micromolar concentration of test compound, n=2Float
17Luminecence_0.05uM (0.05μM**)Average luminescence measured with 0.05 micromolar concentration of test compound, n=2Float
18Luminecence_0.14uM (0.14μM**)Average luminescence measured with 0.14 micromolar concentration of test compound, n=2Float
19Luminecence_0.41uM (0.41μM**)Average luminescence measured with 0.41 micromolar concentration of test compound, n=2Float
20Luminecence_1.23uM (1.23μM**)Average luminescence measured with 1.23 micromolar concentration of test compound, n=2Float
21Luminecence_3.7uM (3.72μM**)Average luminescence measured with 3.72 micromolar concentration of test compound, n=2Float
22Luminecence_11.11uM (11.22μM**)Average luminescence measured with 11.22 micromolar concentration of test compound, n=2Float
23Luminecence_33.33uM (33.11μM**)Average luminescence measured with 33.11 micromolar concentration of test compound, n=2Float
24Luminecence_100uM (100μM**)Average luminescence measured with 100 micromolar concentration of test compound, n=2Float

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: R03 MH093192-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: